Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) has been given a consensus rating of “Hold” by the seven analysts that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $24.67.

A number of equities research analysts have commented on the stock. BidaskClub raised shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Zacks Investment Research lowered shares of Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Canaccord Genuity set a $22.00 price objective on shares of Aquinox Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 8th. Finally, ValuEngine raised shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 2nd.

Institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its position in Aquinox Pharmaceuticals by 10.0% during the 1st quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock valued at $2,028,000 after purchasing an additional 11,035 shares during the period. Archon Partners LLC lifted its position in Aquinox Pharmaceuticals by 44.0% during the 2nd quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock valued at $253,000 after purchasing an additional 5,500 shares during the period. Investment Centers of America Inc. acquired a new position in Aquinox Pharmaceuticals during the 1st quarter valued at about $172,000. Alps Advisors Inc. lifted its position in Aquinox Pharmaceuticals by 4.7% during the 2nd quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock valued at $297,000 after purchasing an additional 939 shares during the period. Finally, Nexthera Capital LP acquired a new position in Aquinox Pharmaceuticals during the 2nd quarter valued at about $1,276,000. Institutional investors own 95.15% of the company’s stock.

Aquinox Pharmaceuticals (AQXP) traded down 9.19% during mid-day trading on Friday, hitting $12.85. 230,748 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $14.28 and a 200 day moving average of $14.77. The stock’s market capitalization is $301.51 million. Aquinox Pharmaceuticals has a 52 week low of $9.83 and a 52 week high of $19.97.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.59) EPS for the quarter, hitting analysts’ consensus estimates of ($0.59). Equities analysts forecast that Aquinox Pharmaceuticals will post ($2.15) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/09/16/aquinox-pharmaceuticals-inc-aqxp-given-consensus-recommendation-of-hold-by-analysts.html.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.